AstraZeneca PLC still intends to apply for a US Food and Drug Administration emergency use authorization of its coronavirus vaccine, but preparations are taking longer than predecessors, potentially influenced by the appearance of rare blood clots among recipients.
Thirty-one days have passed since the company announced positive interim Phase III data for its proposed vaccine, AZD1222, on 22...







